MicroRNA-155 deficiency leads to decreased atherosclerosis, increased white adipose tissue obesity, and non-alcoholic fatty liver disease a novel mouse model of obesity paradox

Journal of Biological Chemistry

Volumn 292, Issue 4, 2017, Pages 1267-1287

  Virtue, Anthony ^a   Johnson, Candice ^a   Lopez Pastraña, Jahaira ^a   Shao, Ying ^a   Fu, Hangfei ^a   Li, Xinyuan ^a   Li, Ya Feng ^a   Yin, Ying ^a   Mai, Jietang ^a   Rizzo, Victor ^a   Tordoff, Michael ^b   Bagi, Zsolt ^c   Shan, Huimin ^a   Jiang, Xiaohua ^a   Wang, Hong ^a   Yang, Xiao Feng ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MONELL CHEMICAL SENSES CENTER   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; MAMMALS; NUTRITION; RNA;

ADIPOCYTE HYPERTROPHY; CARDIOVASCULAR FITNESS; DIET-INDUCED OBESITY; MOLECULAR MECHANISM; NON-ALCOHOLIC FATTY LIVER DISEASE; POTENTIAL MECHANISM; THERAPEUTIC TARGETS; WHITE ADIPOSE TISSUES;

DISEASES;

APOLIPOPROTEIN E; INSULIN; LEPTIN; MICRORNA 155; RESISTIN; TRANSCRIPTION FACTOR; FAT INTAKE; MICRORNA; MIRN155 MICRORNA, MOUSE;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTIC ATHEROSCLEROSIS; AORTIC ENDOTHELIAL CELL; ARTICLE; BODY WEIGHT; CELL ENLARGEMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FLOW CYTOMETRY; GLUCOSE INTOLERANCE; INSULIN RESISTANCE; LIPID DIET; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; OBESITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; UPREGULATION; WHITE ADIPOSE TISSUE; ADVERSE EFFECTS; ANIMAL; ATHEROSCLEROSIS; CHEMICALLY INDUCED; DEFICIENCY; DISEASE MODEL; FAT INTAKE; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PHARMACOLOGY;

ADIPOSE TISSUE, WHITE; ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; DIETARY FATS; DISEASE MODELS, ANIMAL; MICE; MICE, KNOCKOUT; MICRORNAS; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY;

EID: 85020629650     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M116.739839     Document Type: Article

References (69)

1. Hansson, G. K., and Hermansson, A. (2011) The immune system in atherosclerosis. Nat. Immunol. 12, 204-212
2. Anstee, Q. M., Targher, G., and Day, C. P. (2013) Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat. Rev. Gastroenterol. Hepatol. 10, 330-344
3. Lavie, C. J., Alpert, M. A., Arena, R., Mehra, M. R., Milani, R. V., and Ventura, H. O. (2013) Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure. JACC Heart Fail. 1, 93-102
4. Niedziela, J., Hudzik, B., Niedziela, N., Gsior, M., Gierlotka, M., Wasilewski, J., Myrda, K., Lekston, A., Poloński, L., and Rozentryt, P. (2014) The obesity paradox in acute coronary syndrome: a meta-analysis. Eur. J. Epidemiol. 29, 801-812
5. Gurm, H. S., Brennan, D. M., Booth, J., Tcheng, J. E., Lincoff, A. M., and Topol, E. J. (2002) Impact of body mass index on outcome after percutaneous coronary intervention (the obesity paradox). Am. J. Cardiol. 90, 42-45
6. Khattab, A. A., Daemen, J., Richardt, G., Rioux, P., Amann, F. W., Levy, R., Horvath, I. G., Teles, R. C., Ordoubadi, F., Pieters, M., Wittebols, K., Stoll, H. P., and Serruys, P. W. (2008) Impact of body mass index on the one-year clinical outcome of patients undergoing multivessel revascularization with sirolimus-eluting stents (from the Arterial Revascularization Therapies Study Part II). Am. J. Cardiol. 101, 1550-1559
7. Lavie, C. J., De Schutter, A., and Milani, R. V. (2015) Healthy obese versus unhealthy lean: the obesity paradox. Nat. Rev. Endocrinol. 11, 55-62
8. Gregor, M. F., and Hotamisligil, G. S. (2011) Inflammatory mechanisms in obesity. Annu. Rev. Immunol. 29, 415-445
9. Rocha, V. Z., and Libby, P. (2009) Obesity, inflammation, and atherosclerosis. Nat. Rev. Cardiol. 6, 399-409
10. Mestas, J., and Ley, K. (2008) Monocyte-endothelial cell interactions in the development of atherosclerosis. Trends Cardiovasc. Med. 18, 228-232
11. Yin, Y., Li, X., Sha, X., Xi, H., Li, Y. F., Shao, Y., Mai, J., Virtue, A., Lopez-Pastrana, J., Meng, S., Tilley, D. G., Monroy, M. A., Choi, E. T., Thomas, C. J., Jiang, X., Wang, H., and Yang, X. F. (2015) Early hyperlipidemia promotes endothelial activation via a caspase-1-sirtuin 1 pathway. Arterioscler. Thromb. Vasc. Biol. 35, 804-816
12. Sha, X., Meng, S., Li, X., Xi, H., Maddaloni, M., Pascual, D. W., Shan, H., Jiang, X., Wang, H., and Yang, X. F. (2015) Interleukin-35 inhibits endothelial cell activation by suppressing MAPK-AP-1 pathway. J. Biol. Chem. 290, 19307-19318
13. Fang, P., Zhang, D., Cheng, Z., Yan, C., Jiang, X., Kruger, W. D., Meng, S., Arning, E., Bottiglieri, T., Choi, E. T., Han, Y., Yang, X. F., and Wang, H. (2014) Hyperhomocysteinemia potentiates hyperglycemia-induced inflammatory monocyte differentiation and atherosclerosis. Diabetes 63, 4275-4290
14. Zhang, D., Fang, P., Jiang, X., Nelson, J., Moore, J. K., Kruger, W. D., Berretta, R. M., Houser, S. R., Yang, X., and Wang, H. (2012) Severe hyperhomocysteinemia promotes bone marrow-derived and resident inflammatory monocyte differentiation and atherosclerosis in LDLr/CBSdeficient mice. Circ. Res. 111, 37-49
15. Zhang, D., Jiang, X., Fang, P., Yan, Y., Song, J., Gupta, S., Schafer, A. I., Durante, W., Kruger, W. D., Yang, X., and Wang, H. (2009) Hyperhomocysteinemia promotes inflammatory monocyte generation and accelerates atherosclerosis in transgenic cystathionine β-synthase-deficient mice. Circulation 120, 1893-1902
16. Xiong, Z., Song, J., Yan, Y., Huang, Y., Cowan, A., Wang, H., and Yang, X. F. (2008) Higher expression of Bax in regulatory T cells increases vascular inflammation. Front. Biosci. 13, 7143-7155
17. Xiong, Z., Yan, Y., Song, J., Fang, P., Yin, Y., Yang, Y., Cowan, A., Wang, H., and Yang, X. F. (2009) Expression of TCTP antisense in CD25 (high) regulatory T cells aggravates cuff-injured vascular inflammation. Atherosclerosis 203, 401-408
18. Virtue, A., Mai, J., Yin, Y., Meng, S., Tran, T., Jiang, X., Wang, H., and Yang, X. F. (2011) Structural evidence of anti-atherogenic microRNAs. Front. Biosci. (Landmark Ed.) 16, 3133-3145
19. Virtue, A., Wang, H., and Yang, X. F. (2012) MicroRNAs and toll-like receptor/interleukin-1 receptor signaling. J. Hematol. Oncol. 5, 66
20. O'Connell, R. M., Rao, D. S., and Baltimore, D. (2012) microRNA regulation of inflammatory responses. Annu. Rev. Immunol. 30, 295-312
21. Sun, X., Belkin, N., and Feinberg, M. W. (2013) Endothelial microRNAs and atherosclerosis. Curr. Atheroscler. Rep. 15, 372
22. Raitoharju, E., Oksala, N., and Lehtimaki, T. (2013) MicroRNAs in the atherosclerotic plaque. Clin. Chem. 59, 1708-1721
23. Deiuliis, J. A. (2015) MicroRNAs as regulators of metabolic disease: pathophysiologic significance and emerging role as biomarkers and therapeutics. Int. J. Obes. (Lond) 40, 88-101 (10.1038/ijo.2015.170)
24. Ferreira, D. M., Simao, A. L., Rodrigues, C. M., and Castro, R. E. (2014) Revisiting the metabolic syndrome and paving the way for microRNAs in non-alcoholic fatty liver disease. FEBS J. 281, 2503-2524
25. Donners, M. M., Wolfs, I. M., Stoger, L. J., van der Vorst, E. P., Pottgens, C. C., Heymans, S., Schröen, B., Gijbels, M. J., and de Winther, M. P. (2012) Hematopoietic miR155 deficiency enhances atherosclerosis and decreases plaque stability in hyperlipidemic mice. PloS ONE 7, e35877
26. Zhu, N., Zhang, D., Chen, S., Liu, X., Lin, L., Huang, X., Guo, Z., Liu, J., Wang, Y., Yuan, W., and Qin, Y. (2011) Endothelial enriched microRNAs regulate angiotensin II-induced endothelial inflammation and migration. Atherosclerosis 215, 286-293
27. Cheng, W., Liu, T., Jiang, F., Liu, C., Zhao, X., Gao, Y., Wang, H., and Liu, Z. (2011) microRNA-155 regulates angiotensin II type 1 receptor expression in umbilical vein endothelial cells from severely pre-eclamptic pregnant women. Int. J. Mol. Med. 27, 393-399
28. Pulkkinen, K. H., Ylä-Herttuala, S., and Levonen, A. L. (2011) Heme oxygenase 1 is induced by miR-155 via reduced BACH1 translation in endothelial cells. Free Radic. Biol. Med. 51, 2124-2131
29. Sun, H. X., Zeng, D. Y., Li, R. T., Pang, R. P., Yang, H., Hu, Y. L., Zhang, Q., Jiang, Y., Huang, L. Y., Tang, Y. B., Yan, G. J., and Zhou, J. G. (2012) Essential role of microRNA-155 in regulating endothelium-dependent vasorelaxation by targeting endothelial nitric oxide synthase. Hypertension 60, 1407-1414
30. Zhu, J., Chen, T., Yang, L., Li, Z., Wong, M. M., Zheng, X., Pan, X., Zhang, L., and Yan, H. (2012) Regulation of microRNA-155 in atherosclerotic inflammatory responses by targeting MAP3K10. PloS ONE 7, e46551
31. Rodriguez, A., Vigorito, E., Clare, S., Warren, M. V., Couttet, P., Soond, D. R., van Dongen, S., Grocock, R. J., Das, P. P., Miska, E. A., Vetrie, D., Okkenhaug, K., Enright, A. J., Dougan, G., Turner, M., and Bradley, A. (2007) Requirement of bic/microRNA-155 for normal immune function. Science 316, 608-611
32. Thai, T. H., Calado, D. P., Casola, S., Ansel, K. M., Xiao, C., Xue, Y., Murphy, A., Frendewey, D., Valenzuela, D., Kutok, J. L., Schmidt-Supprian, M., Rajewsky, N., Yancopoulos, G., Rao, A., and Rajewsky, K. (2007) Regulation of the germinal center response by microRNA-155. Science 316, 604-608
33. Nazari-Jahantigh, M., Wei, Y., Noels, H., Akhtar, S., Zhou, Z., Koenen, R. R., Heyll, K., Gremse, F., Kiessling, F., Grommes, J., Weber, C., and Schober, A. (2012) MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in macrophages. The Journal of clinical investigation 122, 4190-4202
34. Chen, Y., Siegel, F., Kipschull, S., Haas, B., Fröhlich, H., Meister, G., and Pfeifer, A. (2013) miR-155 regulates differentiation of brown and beige adipocytes via a bistable circuit. Nat. Commun. 4, 1769
35. Klöting, N., Berthold, S., Kovacs, P., Schön, M. R., Fasshauer, M., Ruschke, K., Stumvoll, M., and Blüher, M. (2009) MicroRNA expression in human omental and subcutaneous adipose tissue. PloS ONE 4, e4699
36. Economou, E. K., Oikonomou, E., Siasos, G., Papageorgiou, N., Tsalamandris, S., Mourouzis, K., Papaioanou, S., and Tousoulis, D. (2015) The role of microRNAs in coronary artery disease: from pathophysiology to diagnosis and treatment. Atherosclerosis 241, 624-633
37. Hosin, A. A., Prasad, A., Viiri, L. E., Davies, A. H., and Shalhoub, J. (2014) MicroRNAs in atherosclerosis. J. Vasc. Res. 51, 338-349
38. Doherty, T. M., Shah, P. K., and Arditi, M. (2005) Lipopolysaccharide, toll-like receptors, and the immune contribution to atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 25, e38
39. Nogueras, S., Merino, A., Ojeda, R., Carracedo, J., Rodriguez, M., Martin-Malo, A., Ramírez, R., and Aljama, P. (2008) Coupling of endothelial injury and repair: an analysis using an in vivo experimental model. Am. J. Physiol. Heart Circ. Physiol. 294, H708-H713
40. Skårn, M., Namløs, H. M., Noordhuis, P., Wang, M. Y., Meza-Zepeda, L. A., and Myklebost, O. (2012) Adipocyte differentiation of human bone marrow-derived stromal cells is modulated by microRNA-155, microRNA-221, and microRNA-222. Stem Cells Dev. 21, 873-883
41. Coppieters, K. T., and von Herrath, M. G. (2014) Metabolic syndrome; removing roadblocks to therapy: antigenic immunotherapies. Mol. Metab. 3, 275-283
42. Du, F., Yu, F., Wang, Y., Hui, Y., Carnevale, K., Fu, M., Lu, H., and Fan, D. (2014) MicroRNA-155 deficiency results in decreased macrophage inflammation and attenuated atherogenesis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 34, 759-767
43. Nakashima, Y., Plump, A. S., Raines, E. W., Breslow, J. L., and Ross, R. (1994) apoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler. Thromb. 14, 133-140
44. Huang, Y., Liu, X. Q., Rall, S. C., Jr, Taylor, J. M., von Eckardstein, A., Assmann, G., and Mahley, R. W. (1998) Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia. J. Biol. Chem. 273, 26388-26393
45. Tang, T., Zhang, J., Yin, J., Staszkiewicz, J., Gawronska-Kozak, B., Jung, D. Y., Ko, H. J., Ong, H., Kim, J. K., Mynatt, R., Martin, R. J., Keenan, M., Gao, Z., and Ye, J. (2010) Uncoupling of inflammation and insulin resistance by NF-κB in transgenic mice through elevated energy expenditure. J. Biol. Chem. 285, 4637-4644
46. Spalding, K. L., Arner, E., Westermark, P. O., Bernard, S., Buchholz, B. A., Bergmann, O., Blomqvist, L., Hoffstedt, J., Näslund, E., Britton, T., Concha, H., Hassan, M., Rydén, M., Frisén, J., and Arner, P. (2008) Dynamics of fat cell turnover in humans. Nature 453, 783-787
47. Sun, K., Kusminski, C. M., and Scherer, P. E. (2011) Adipose tissue remodeling and obesity. J. Clin. Investig. 121, 2094-2101
48. Wang, Q. A., Tao, C., Gupta, R. K., and Scherer, P. E. (2013) Tracking adipogenesis during white adipose tissue development, expansion, and regeneration. Nat. Med. 19, 1338-1344
49. Van Gaal, L. F., Mertens, I. L., and De Block, C. E. (2006) Mechanisms linking obesity with cardiovascular disease. Nature 444, 875-880
50. Lakner, A. M., Bonkovsky, H. L., and Schrum, L. W. (2011) microRNAs: fad or future of liver disease. World J. Gastroenterol. 17, 2536-2542
51. Miller, A. M., Gilchrist, D. S., Nijjar, J., Araldi, E., Ramirez, C. M., Lavery, C. A., Fernández-Hernando, C., McInnes, I. B., and Kurowska-Stolarska, M. (2013) MiR-155 has a protective role in the development of non-alcoholic hepatosteatosis in mice. PloS ONE 8, e72324
52. Bjørndal, B., Burri, L., Staalesen, V., Skorve, J., and Berge, R. K. (2011) Different adipose depots: their role in the development of metabolic syndrome and mitochondrial response to hypolipidemic agents. J. Obes. 2011, 490650
53. Considine, R. V., Sinha, M. K., Heiman, M. L., Kriauciunas, A., Stephens, T. W., Nyce, M. R., Ohannesian, J. P., Marco, C. C., McKee, L. J., and Bauer, T. L. (1996) Serum immunoreactive-leptin concentrations in normalweight and obese humans. N. Engl. J. Med. 334, 292-295
54. Degawa-Yamauchi, M., Bovenkerk, J. E., Juliar, B. E., Watson, W., Kerr, K., Jones, R., Zhu, Q., and Considine, R. V. (2003) Serum resistin (FIZZ3) protein is increased in obese humans. J. Clin. Endocrinol. Metab. 88, 5452-5455
55. Wang, B., Chandrasekera, P. C., and Pippin, J. J. (2014) Leptin- and leptin receptor-deficient rodent models: relevance for human type 2 diabetes. Curr. Diabetes Rev. 10, 131-145
56. Gruberg, L., Weissman, N. J., Waksman, R., Fuchs, S., Deible, R., Pinnow, E. E., Ahmed, L. M., Kent, K. M., Pichard, A. D., Suddath, W. O., Satler, L. F., and Lindsay, J., Jr. (2002) The impact of obesity on the short-term and long-term outcomes after percutaneous coronary intervention: the obesity paradox? J. Am. Coll. Cardiol. 39, 578-584
57. Dixon, J. B., Egger, G. J., Finkelstein, E. A., Kral, J. G., and Lambert, G. W. (2015) "Obesity paradox" misunderstands the biology of optimal weight throughout the life cycle. Int. J. Obes. (Lond) 39, 82-84 (10.1038/ijo.2014.59)
58. Hainer, V., and Aldhoon-Hainerová, I. (2013) Obesity paradox does exist. Diabetes care 36, S276-S281
59. Kortelainen, M. L., and Porvari, K. (2011) Extreme obesity and associated cardiovascular disease verified at autopsy: time trends over 3 decades. Am. J. Forensic Med. Pathol. 32, 372-377
60. Zhang, S. H., Reddick, R. L., Piedrahita, J. A., and Maeda, N. (1992) Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 258, 468-471
61. Bäck, M., and Hansson, G. K. (2015) Anti-inflammatory therapies for atherosclerosis. Nat. Rev. Cardiol. 12, 199-211
62. Raitoharju, E., Lyytikäinen, L. P., Levula, M., Oksala, N., Mennander, A., Tarkka, M., Klopp, N., Illig, T., Kähönen, M., Karhunen, P. J., Laaksonen, R., and Lehtimäki, T. (2011) miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques in the Tampere Vascular Study. Atherosclerosis 219, 211-217
63. Ortega, F. B., Lavie, C. J., and Blair, S. N. (2016) Obesity and cardiovascular disease. Circ. Res. 118, 1752-1770
64. Wang, F., Deeney, J. T., and Denis, G. V. (2013) Brd2 gene disruption causes "metabolically healthy" obesity: epigenetic and chromatin-based mechanisms that uncouple obesity from type 2 diabetes. Vitam. Horm. 91, 49-75
65. Androulidaki, A., Iliopoulos, D., Arranz, A., Doxaki, C., Schworer, S., Zacharioudaki, V., Margioris, A. N., Tsichlis, P. N., and Tsatsanis, C. (2009) The kinase Akt1 controls macrophage response to lipopolysaccharide by regulating microRNAs. Immunity 31, 220-231
66. Steppan, C. M., Bailey, S. T., Bhat, S., Brown, E. J., Banerjee, R. R., Wright, C. M., Patel, H. R., Ahima, R. S., and Lazar, M. A. (2001) The hormone resistin links obesity to diabetes. Nature 409, 307-312
67. Banerjee, R. R., Rangwala, S. M., Shapiro, J. S., Rich, A. S., Rhoades, B., Qi, Y., Wang, J., Rajala, M. W., Pocai, A., Scherer, P. E., Steppan, C. M., Ahima, R. S., Obici, S., Rossetti, L., and Lazar, M. A. (2004) Regulation of fasted blood glucose by resistin. Science 303, 1195-1198
68. Wu, D., Molofsky, A. B., Liang, H. E., Ricardo-Gonzalez, R. R., Jouihan, H. A., Bando, J. K., Chawla, A., and Locksley, R. M. (2011) Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science 332, 243-247
69. Yadav, H., Quijano, C., Kamaraju, A. K., Gavrilova, O., Malek, R., Chen, W., Zerfas, P., Zhigang, D., Wright, E. C., Stuelten, C., Sun, P., Lonning, S., Skarulis, M., Sumner, A. E., Finkel, T., and Rane, S. G. (2011) Protection from obesity and diabetes by blockade of TGF-β/Smad3 signaling. Cell. Metab. 14, 67-79